NLS Pharmaceutics Reports Results From Study KO-874 On Mazindol's Neuroprotective Effects In Narcoleptic-Like Rat Model
NLS Pharmaceutics Reports Results From Study KO-874 On Mazindol's Neuroprotective Effects In Narcoleptic-Like Rat Model
NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company dedicated to pioneering therapies for rare and complex central nervous system disorders, today announced promising results from its preclinical study KO-874 at the American Society of Clinical Psychopharmacology (ASCP) in Miami. This study evaluated the neuroprotective effects of mazindol on nocturnal activity in a rat model with narcoleptic-like symptoms induced by orexin-B-saporin (OX-B-SAP) lesions in the lateral hypothalamus (LH).
瑞士臨床階段生物製藥公司NLS Pharmaceutics Ltd.（納斯達克股票代碼：NLSP，NLSPW）（以下簡稱“NLS”或“公司”）致力於開創罕見和複雜的中樞神經系統疾病的治療方法，並在美國臨床精神藥理學會（ASCP）在邁阿密舉行的會議上，發佈了KO-874臨床前研究的良好結果。該研究評估了Ma的神經保護作用在一種老鼠夜間活動模型中的效果，該模型由側下丘腦（LH）中orexin-B-saporin（OX-B-SAP）病變誘導的阿魏酸鹽類似症狀引起。